Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 1999

View Archived Issues

NCI to conduct further testing of Lorus anticancer compounds

Genzyme General: Q4 and year-end 1998 highlights

Xoma continues patient enrollment in phase III meningococcemia trial

Techniclone enters licensing agreement for Oncolym with Schering AG

New U.S. patent broadens the base of ImmunoGen's TAP technology

Roberts acquires Lodine rights in the U.K. and Ireland

Amgen and Praecis to develop and commercialize abarelix

Hyseq: Q4 and year-end 1998 highlights

ImClone receives milestone payment for C225 clinical advance

U.K. is country of first launch for Schering-Plough's oral alkylating agent

Kynurenine 3-monooxygenase inhibitors for neurodegenerative disorders

Dual vasopeptidase inhibitor omapatrilat reduces blood pressure in healthy volunteers

Warner-Lambert prepares irreversible tyrosine kinase inhibitors

GABA-A alpha5 subunit-selective inverse agonists from Merck useful for Alzheimer's disease

Recordati claims potent and selective 5-HT1A receptor antagonists for urinary disorders

Orally active, selective V2 agonists in development at AHP

FDA okays new indication and minimal liver function testing for Lescol

Ad.VEGF121 preserves blood flow to ischemic tissues in animal models

Sonus adds new patent to its ultrasound contrast agent portfolio

ACC highlights: UT-15 effective and safe in severe intermittent claudication

Biosense and RPR Gencell to develop innovative gene therapy to treat heart disease

Sangamo enters agreement with Japan Tobacco for validation of novel gene targets

Genentech reports results on TNK-tPA from TIMI 10B and ASSENT 1 at ACC meeting

Procept's PRO-2000 Gel shows positive results in protection from HIV infection

Diltiazem plus aspirin for secondary prevention following thrombolysis in MI patients

FDA grants fast track designation for pneumococcal conjugate vaccine

LU-135252 may be useful in AMI patients according to data presented at ACC meeting

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.